Related Experiment Videos
Vomiting of liquid corticosteroids in children with asthma
Michael K Kim1, Kenneth Yen, Ryan L Redman
1Section of Emergency Medicine, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USA. mkim@mcw.edu
Insights
Orapred significantly reduced vomiting and improved taste in children with asthma exacerbations compared to generic prednisolone. This new formulation offers a better-tolerated oral corticosteroid option for pediatric patients.
Area of Science:
- Pediatric Emergency Medicine
- Pharmacology
- Clinical Therapeutics
Background:
- Oral corticosteroids are crucial for managing pediatric acute asthma exacerbations.
- Vomiting is a common adverse effect associated with oral corticosteroids in children.
- A novel prednisolone formulation, Orapred, aims to improve palatability and reduce vomiting incidence.
Purpose of the Study:
- To compare the incidence of vomiting between Orapred and generic prednisolone in children.
- To evaluate and compare the taste experience of Orapred versus generic prednisolone.
- To assess the efficacy of Orapred in mitigating a common side effect of oral steroid treatment.
Main Methods:
- A randomized, double-blind clinical trial was conducted in a pediatric emergency department.
- Children aged 2-10 years with acute asthma exacerbations received either generic prednisolone or Orapred.
- Vomiting was observed for 30 minutes post-administration; taste was assessed using a hedonic scale for children aged 6+.
Main Results:
- 188 children were analyzed: 96 received generic prednisolone and 92 received Orapred.
- Vomiting occurred in 17.7% of the generic prednisolone group versus 5.4% in the Orapred group (RR = 3.26).
- The median taste score was significantly better for Orapred (4) compared to generic prednisolone (2) (P = 0.0001).
Conclusions:
- Orapred demonstrated a significantly lower incidence of vomiting in children with acute asthma exacerbations.
- The Orapred formulation was associated with a superior taste profile compared to generic prednisolone.
- Orapred represents a more palatable and better-tolerated alternative for oral corticosteroid therapy in pediatric asthma.
Background:
Oral corticosteroids are an essential part of the management of children with acute asthma exacerbations. Vomiting is a frequently cited problem attributed to oral corticosteroids. A new formulation of prednisolone, Orapred, claims to have improved palatability that may decrease the incidence of vomiting.
Objective:
To compare the incidence of vomiting and taste between patients who are given the generic preparation of prednisolone with those given Orapred.
Design/Methods:
A randomized, double blind clinical trial was conducted at a tertiary care children s hospital emergency department. Children age 2 to 10 years presenting with acute asthma exacerbation were eligible. Patients with allergy to prednisolone, corticosteroid use within 2 weeks, history of vomiting in the last 24 hours, requirement for vascular access, and preference for other forms of corticosteroid were excluded. Enrolled patients were randomized and given either generic prednisolone (15 mg/5 ml) or Orapred (15 mg/5 ml). In children 6 years or older, a taste score was obtained using a 5 point hedonic face scale (1 = bad to 5 = great). After the administration, patients were observed for 30 minutes for vomiting. The Mann-Whitney U test was used to compare the median taste score between the two study groups. Relative risk (RR) of vomiting was calculated. Other confidence intervals were calculated when appropriate.
Results:
During the study period, 211 eligible children were enrolled, of whom 23 were excluded. Of the remaining 188 subjects, 96 received generic prednisolone and 92 received Orapred. All baseline characteristics were similar in both groups. In the generic prednisolone group, 17 (17.7%) children vomited compared with 5 (5.4%) in the Orapred group (RR = 3.26, 95% CI, 1.25, 8.47). Taste scores were obtained from 18 children in the generic prednisolone group and from 19 children in the Orapred group. The median taste score was 2 for the generic prednisolone group and 4 for the Orapred group (Delta = -2.0, 95% CI, -3.0, -1.0) (P = 0.0001).
Conclusions:
In our study population, Orapred was associated with a significant less incidence of vomiting and better taste score compared to the generic prednisolone.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:13Asthma III: Clinical Manifestations
01:22Pathophysiology of Vomiting
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.